Coronavirus (COVID-19) vaccination rates among adults who live in England, including estimates by socio-demographic characteristic and Standard Occupational Classification (SOC) 2020

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

Vaccinations in London Between 8 December 2020 and 15 September 2021 5,838,305 1st doses and 5,232,885 2nd doses have been administered to London residents. Differences in vaccine roll out between London and the Rest of England London Rest of England Priority Group Vaccinations given Percentage vaccinated Vaccinations given Percentage vaccinated Group 1 Older Adult Care Home Residents 21,883 95% 275,964 96% Older Adult Care Home Staff 29,405 85% 381,637 88% Group 2 80+ years 251,021 83% 2,368,284 93% Health Care Worker 174,944 99% 1,139,243 100%* Group 3 75 - 79 years 177,665 90% 1,796,408 99% Group 4 70 - 74 years 252,609 90% 2,454,381 97% Clinically Extremely Vulnerable 278,967 88% 1,850,485 95% Group 5 65 - 69 years 285,768 90% 2,381,250 97% Group 6 At Risk or Carer (Under 65) 983,379 78% 6,093,082 88% Younger Adult Care Home Residents 3,822 92% 30,321 93% Group 7 60 - 64 years 373,327 92% 2,748,412 98% Group 8 55 - 59 years 465,276 91% 3,152,412 97% Group 9 50 - 54 years 510,132 90% 3,141,219 95% Data as at 15 September 2021 for age based groups and as at 12 September 2021 for non-age based groups * The number who have received their first dose exceeds the latest official estimate of the population for this group There is considerable uncertainty in the population denominators used to calculate the percentage vaccinated. Comparing implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following datasets can be used to estimate vaccine uptake by age group for London: ONS 2020 mid-year estimates (MYE). This is the population estimate used for age groups throughout the rest of the analysis. Number of people ages 18 and over on the National Immunisation Management Service (NIMS) ONS Public Health Data Asset (PHDA) dataset. This is a linked dataset combining the 2011 Census, the General Practice Extraction Service (GPES) data for pandemic planning and research and the Hospital Episode Statistics (HES). This data covers a subset of the population. Vaccine roll out in London by Ethnic Group Understanding how vaccine uptake varies across different ethnic groups in London is complicated by two issues: Ethnicity information for recipients is unavailable for a very large number of the vaccinations that have been delivered. As a result, estimates of vaccine uptake by ethnic group are highly sensitive to the assumptions about and treatment of the Unknown group in calculations of rates. For vaccinations given to people aged 50 and over in London nearly 10% do not have ethnicity information available, The accuracy of available population denominators by ethnic group is limited. Because ethnicity information is not captured in official estimates of births, deaths, and migration, the available population denominators typically rely on projecting forward patterns captured in the 2011 Census. Subsequent changes to these patterns, particularly with respect to international migration, leads to increasing uncertainty in the accuracy of denominators sources as we move further away from 2011. Comparing estimated population sizes and implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following population estimates are available by Ethnic group for London:

Includes: Patient demographics, Source Organisation, vaccination details and vaccine batch events. Its scope covers: Anyone vaccinated within England Anyone vaccinated in a Devoted Administration where this information is subsequently passed to England.

Settings include: hospital hubs - NHS providers vaccinating on site local vaccine services – community or primary care led services which could include primary care facilities, retail, community facilities, temporary structures or roving teams vaccination centres – large sites such as sports and conference venues set up for high volumes of people

Timescales for dissemination can be found under 'Our Service Levels' at the following link: https://digital.nhs.uk/services/data-access-request-service-dars/data-access-request-service-dars-process

Antibody data, by UK country and age, from the Coronavirus (COVID-19) Infection Survey.

Dataset no longer updated: Due to changes in the collection and availability of data on COVID-19, this dataset is no longer updated. Latest information about COVID-19 is available via the UKHSA data dashboard. The UK government publish daily data, updated weekly, on COVID-19 cases, vaccinations, hospital admissions and deaths. This note provides a summary of the key data for London from this release. Data are published through the UK Coronavirus Dashboard, last updated on 23 March 2023. This update contains: Data on the number of cases identified daily through Pillar 1 and Pillar 2 testing at the national, regional and local authority level Data on the number of people who have been vaccinated against COVID-19 Data on the number of COVID-19 patients in Hospital Data on the number of people who have died within 28 days of a COVID-19 diagnosis Data for London and London boroughs and data disaggregated by age group Data on weekly deaths related to COVID-19, published by the Office for National Statistics and NHS, is also available. Key Points On 23 March 2023 the daily number of people tested positive for COVID-19 in London was reported as 2,775 On 23 March 2023 it was newly reported that 94 people in London died within 28 days of a positive COVID-19 test The total number of COVID-19 cases identified in London to date is 3,146,752 comprising 15.2 percent of the England total of 20,714,868 cases In the most recent week of complete data (12 March 2023 - 18 March 2023) 2,951 new cases were identified in London, a rate of 33 cases per 100,000 population. This compares with 2,883 cases and a rate of 32 for the previous week In England as a whole, 29,426 new cases were identified in the most recent week of data, a rate of 52 cases per 100,000 population. This compares with 26,368 cases and a rate of 47 for the previous week Up to and including 22 March 2023 6,452,895 people in London had received the first dose of a COVID-19 vaccine and 6,068,578 had received two doses Up to and including 22 March 2023 4,435,586 people in London had received either a third vaccine dose or a booster dose On 22 March 2023 there were 1,370 COVID-19 patients in London hospitals. This compares with 1,426 patients on 15 March 2023. On 22 March 2023 there were 70 COVID-19 patients in mechanical ventilation beds in London hospitals. This compares with 72 patients on 15 March 2023. Update: From 1st July updates are weekly From Friday 1 July 2022, this page will be updated weekly rather than daily. This change results from a change to the UK government COVID-19 Dashboard which will move to weekly reporting. Weekly updates will be published every Thursday. Daily data up to the most recent available will continue to be added in each weekly update. Data summary Local authority data Demographics Notes on data sources Source: UK Coronavirus Dashboard. For more information see: Coronavirus (COVID-19) in the UK - About the Data. Cases Data UK Health Security Agency (UKHSA) reports new and cumulative cases identified by Pillar 1 and Pillar 2 testing. Pillar 1 testing relates to tests carried out in UKHSA laboratories or NHS Hospitals for those with clinical need, and health and care workers. Pillar 2 testing relates to tests carried out on the wider population in Lighthouse laboratories, public, private, and academic sector laboratories or using lateral flow devices. The cases data is published by day for Countries within the UK, and Regions, Upper Tier Local Authority (UTLA) and Lower Tier Local Authority (LTLA) within England. The data used here is taken from the regional and UTLA level cases data. Notice: Changes to COVID-19 case reporting As of 31 January 2022, UKHSA moved all COVID-19 case reporting in England to use an episode-based definition which includes possible reinfections. Those testing positive beyond 90 days of a previous infection are now counted as a separate infection episode (a possible reinfection episode). Previously people who tested positive for COVID-19 were only counted once in case numbers published on the daily dashboard, at the date of the first infection. Full details of the changes can be found here Changes to COVID-19 testing in England The availability of free COVID-19 tests in England changed on 1 April 2022. Information on who can access free tests has been published by UKHSA. Changes to patient testing in the NHS in England have also been published by NHS England. Deaths data Data on COVID-19 associated deaths in England are produced by UKHSA from multiple sources linked to confirmed case data. Deaths are only included if the deceased had a positive test for COVID-19 and died within 28 days of the first positive test. Postcode of residence for deaths is collected at the time of testing. This is supplemented, where available, with information from ONS mortality records, Health Protection Team reports and NHS Digital Patient Demographic Service records. Full details of the methodology are available in the technical summary of the PHE data series on deaths in people with COVID-19. Hospital admissions data UKHSA publish the daily total number of patients admitted to hospital, patients in hospital and patients in beds which can deliver mechanical ventilation with COVID-19. In England this includes COVID-19 patients being treated in NHS acute hospitals, mental health and learning disability trusts, and independent service providers commissioned by the NHS. Vaccination data UKHSA publish the number of people who have received a COVID-19 vaccination, by day on which the vaccine was administered. Data are reported daily and can be updated for historical dates as vaccinations given are recorded on the relevant system. Therefore, data for recent dates may be incomplete. Vaccinations that were carried out in England are reported in the National Immunisation Management Service which is the system of record for the vaccination programme in England. Only people aged 12 and over who have an NHS number and are currently alive are included. Age is defined as a person's age at 31 August 2021. The data includes counts of vaccinations by age band, dose, region, and local authority. Additional analysis of the vaccine roll out in London can be found here. ONS population estimates The counts of vaccines given has been converted to percentage of the population vaccinated using the ONS 2020 mid-year population estimates. This is a different population estimate to that used on the UK Coronavirus Dashboard for sub-national data. The UK Coronavirus Dashboard uses people aged 16 and over in the National Immunisation Management Service (NIMS), which is based on GP registrations. In more urban areas like London, NIMS is likely to give an overestimate of the population due to increased population mobility increasing the likelihood duplicate or out of date GP records. Due to the differences in population estimates the percentage of the population vaccinated given here will be higher than the figures included for London on the UK Coronavirus Dashboard. Data and Resources phe_deaths_age_london.csv Source: https://coronavirus.data.gov.uk/ phe_deaths_london_boroughs.csv Source: https://coronavirus.data.gov.uk/ phe_vaccines_age_london_boroughs.csv

Vaccination rates and odds ratios by socio-demographic group among people living in England.

These data describe pneumococcal polysaccharide vaccine (PPV) uptake for the survey year, for those aged 65 years and over.RationaleVaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Pneumococcal disease is a significant cause of morbidity and mortality. Certain groups are at risk for severe pneumococcal disease, these include young children, the elderly and people who are in clinical risk groups2. Pneumococcal infections can be non invasive such as bronchitis, otitis media or invasive such as septicaemia, pneumonia, meningitis. Cases of invasive pneumococcal infection usually peak in the winter during December and January. The pneumococcal polysaccharide vaccine (PPV) protects against 23 types of Streptococcus pneumoniae bacterium. It is thought that the PPV is around 50 percent to 70 percent effective at preventing more serious types of invasive pneumococcal infection2.Since 1992 the 23 valent PPV has been recommended for people in the clinical risk groups and since 2003, the PPV vaccination programme has expanded to include immunisation to all those aged 65 years and over in England1This indicator was judged to be a valid and an important measure of public health and was therefore included in the public health outcomes framework. Inclusion of these indicators will encourage the continued prioritisation and evaluation and the effectiveness of the PPV vaccination programme and give an indication of uptake at an upper tier Local Authority level. The vaccination surveys measure the proportion of eligible people that have received PPV at any time and the proportion that received PPV during the previous year, providing an opportunity to assess the delivery of the immunisation programme11 Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2013 to March 2014 [online]. 2015 [cited 2015 Mar]. Available from URL: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates 2 Pneumococcal infections, NHS Choices [online]. 2013 [cited 2013 Dec]. Available from URL: http://www.nhs.uk/conditions/vaccinations/pages/pneumococcal-vaccination.aspxDefinition of numeratorUKHSA provided UTLA level data. Clinical commissioning group (CCG) data is available from https://www.gov.uk/government/collections/vaccine-uptake#ppv-vaccine-uptakeDefinition of denominatorNumber of adults aged 65 years and over. Data from 2013 to 2014 are now available at source at a local authority level. Data prior to 2013 to 2014 were collected at a PCT level and converted to LA level for inclusion in PHOF using the criteria as defined below:Denominators for local authorities are estimated from denominators for PCTs. Denominators for PCTs include all people registered with practices accountable to the PCT, and no data are available to provide resident-based figures. Denominators for local authorities are estimated as follows: (For local authorities that have exactly the same boundary as a PCT, the PCT figure is used as it is the only estimate available for the residents of the PCT and local authority. For local authorities whose boundary is contained wholly within a single PCT, but is not equal to the whole PCT, the LA denominator is estimated as a proportion of the PCT figure, with the exceptions of Isles of Scilly, City of London, Rutland, Cornwall, Hackney and Leicestershire (see below). For local authorities whose boundaries include all or part of more than one PCT, the local authority denominator is estimated by aggregating the appropriate proportions of the denominators for the PCTs whose boundaries include part of the local authority. The appropriate proportions in cases ii and iii are defined according to the resident population (in the appropriate age group) in the calendar year overlapping most of the period of the indicator value (or the most recent available): resident population by Lower Layer Super Output Area were extracted and used to calculate the population resident in every LA PCT overlapping block.To calculate the denominator, each LA PCT overlap is calculated as a proportion of the PCT resident population, and then multiplied by the denominator for the PCT. A LA may overlap several PCTs: the appropriate portions of all the PCTs’ denominators are aggregated to give the denominator estimate for the LA. Expressed as an equation the denominator is calculated as follows: DenominatorLA = ∑ (DenominatorPCT × n/N) summed over all PCTs overlapping the LA where: DenominatorLA = Estimated denominator in the LA n = Population resident in the LA-PCT overlapping block N = Population resident in the PCT DenominatorPCT = Denominator in the PCT For Isles of Scilly, City of London and Rutland, no indicator data are presented (prior to 2013 to 2014), as the local authority makes up a very small proportion of the PCT, and estimates for the LAs based on the PCT figures are unlikely to be representative as they are swamped by the much larger local authority within the same PCT. The estimates for Cornwall, Hackney and Leicestershire local authorities are combined data for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland respectively in order to ensure that all valid PCT data are included in the England total.Denominators for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland are not combined for the 2019 to 2020 annual local authority level data."CaveatsThe pneumococcal vaccine uptake collection is a snapshot of GP patients vaccinated currently registered at the time of data extraction. The proportion of GP practices who provided data for the surveys are available from the uptake reports. Data will exclude patients who have received the vaccine but have subsequently died, patients who have since moved, or patients that are vaccinated but have not had their electronic patient record updated by the time of data extraction. Data for local authorities prior to 2013 to 2014 have been estimated from registered PCT level indicators. While the majority of patients registered with practices accountable to a PCT tend to be resident within that PCT, there are, in some PCTs, significant differences between their resident and registered populations. Therefore the estimates for LAs may not always accurately reflect the resident population of the local authority (LA). Please note that the PCT response rate should be checked for data completeness as this will have a knock on effect to the LA values.

https://www.gov.uk/vaccine-damage-payment/if-you-disagree-with-a-decision

Figures on coronavirus (COVID-19) vaccine uptake in school pupils aged 12 to 17 years attending state-funded secondary, sixth form and special schools, broken down by demographic and geographic characteristics, using a linked English Schools Census and National Immunisation Management System dataset. Experimental Statistics.

The number and percentage of Covid-19 fully vaccinated people by age band. Population estimates are based on National Immunisation Management Service counts.This dataset has been updated to reflect new age bandings and population figures provided in July 2022.This dataset now includes details of the Autumn Booster programme.Note on analysis:This datasets presents the proportion of the eligible population who have received all vaccinations they are entitled to. This is terms as a "Complete Dose". The number of vaccinations required to qualify as a complete dose differs by the age of the individual. The following scale is used to determine this:- Aged 5 - 15 - Dose 1- Aged 16 - 24 - Dose 1 & Dose 2- Aged 35 - 50 - Dose 1, Dose 2 & Booster- Aged 50+ - Dose1, Dose2, Booster & Autumn BoosterData is updated weekly.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

Flu vaccine uptake (percent) in at risk individuals aged 6 months to 65 years (excluding pregnant women), who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

Estimates of the risk of all-cause and cardiac death in the 12 weeks after vaccination or positive SARS-CoV-2 test compared with subsequent weeks for people aged 12 to 29 years in England using two sources of mortality data: ONS death registrations and deaths recorded in Hospital Episode Statistics. 8 December 2020 to 25 May 2022. Experimental Statistics.

Flu vaccine uptake (%) in school aged children from Reception to Year 6 (age 4 to 11 year olds) between 1st September to the end of January.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual flu letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 70% vaccine uptake in school aged children in Reception to Year 6 (age 4 to 11 years old).Definition of numeratorThe total number of children in the respective eligible age cohort that have received at least one dose of influenza vaccine from 1 September in school, pharmacy, and general practice.Definition of denominatorThe total number of children eligible for influenza vaccination in the LA geography and children educated out of school in the LA geography, defined by child age on 31 AugustCaveatsData for ICBs are estimated from local authority data. In most cases, ICBs are coterminous with local authorities, so the ICB figures are precise. In cases where local authorities cross ICB boundaries, the local authority data are proportionally split between ICBs, based on the population located in each ICB.The affected ICBs are:Bath and North East Somerset, Swindon and WiltshireBedfordshire, Luton and Milton KeynesBuckinghamshire, Oxfordshire and Berkshire WestCambridgeshire and PeterboroughFrimleyHampshire and Isle of WightHertfordshire and West EssexHumber and North YorkshireLancashire and South CumbriaNorfolk and WaveneyNorth East and North CumbriaSuffolk and North East EssexSurrey HeartlandsSussexWest YorkshireRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus may fall outside the listed read codes. Therefore, it is important to note that for the reasons mentioned, this data should not be used for GP payment purposes.This collection is regularly submitted for approval from the Data Coordination Board (DCB).

Time Use Survey data show changes in how people spent their time during coronavirus (COVID-19) restrictions in March and April 2020, September to October 2020 and March 2021, as well as before the pandemic. It also includes Opinions and Lifestyle Survey data on behaviours following vaccination in Great Britain from 19 May to 13 June 2021.

Does the performance of the EU compared to neighbouring countries affect popular support for the EU? Following the benchmarking approach, we argue that people compare the performance of their country inside the EU with that of a country outside the EU and, as a result of this comparison, form their attitudes towards the EU. The COVID-19 vaccine rollout in 2020 represents an ideal scenario to test this benchmarking expectation. While the pandemic challenged countries across the globe simultaneously, the speed at which governments launched their vaccination programs differed. The UK rolled out its vaccines weeks before EU countries, and we study whether this affected popular support for the EU. We conduct an Unexpected Event during Surveys Design (UESD) based on a Eurobarometer survey in the field when the first vaccine was administered in the UK. Our results show that the start of the COVID-19 vaccination in the UK led to a significant decrease in specific policy support for the EU, while there is no consistent evidence of change in diffuse support for the EU. Our article has important implications for understanding attitudes toward European integration and performance evaluations.

Request ‘Question 1: How much money has so far been allocated to those affected by a Covid vaccination via the Vaccine Damages Payment Scheme? Question 2: How many individuals have made an application to the Vaccine Damages Payment Scheme having been affected by Guillain-Barre syndrome following a coronavirus vaccination? Question 3: How many applications to the Vaccine Damage Payment Scheme following a coronavirus vaccination have successfully resulted in a pay-out in total? Question 4: How many applicants who applied to the Vaccine Damages Payment Scheme on the basis of a Guillain-Barre syndrome diagnosis following a coronavirus vaccination have been successful in their applications and received a payment? (Please also include the number of such applications which remain outstanding and the number of applications which have been rejected) Question 5: How many applicants to the Vaccine Damage Payment Scheme who applied on the basis of a diagnosis of Guillain-Barre syndrome following a coronavirus vaccination were declined on the basis of not meeting the 60% 'severe disability' threshold? Question 6: How many applicants to the Vaccine Damage Payment Scheme who applied on the basis of a diagnosis of Guillain-Barre syndrome following a coronavirus vaccination were declined on the basis that a full or partial recovery was considered to be likely? Question 7: How many individuals made applications to the Vaccine Damage Payment Scheme in Angus, Scotland and how many of these applications were successful, are still outstanding or were unsuccessful? Question 8: How many applications in Angus Scotland to the Vaccine Damage Payment Scheme were made on the basis of a diagnosis of Guillain-Barre syndrome following a coronavirus vaccination? (Please also include how many of these applications were successful, unsuccessful and remain outstanding)’ [On 15 March 2024 you clarified your request as follows] ‘With regard to question 1 I can confirm that my query relates to the total value of Vaccine Damage Payments awarded to COVID-19 claimants rather than the total costs associated with administering the VDPS scheme.’ [On 9 April 2024 your clarified your request as follows] ‘I can confirm that question 7 relates to the claims to the Vaccine Damage Payment which relate to a COVID-19 vaccination. I can confirm that in question 7 & 8 by 'Angus' I intended to refer to the UK Parliamentary constituency of Angus if this information is available. If this information is not available in relation to the Angus UK Parliamentary Constituency, then it would be greatly appreciated if the Angus Council local authority area could be considered for these responses instead.’ Response All data as of 15 March 2024. All data relates to claims received by the NHS Business Services Authority (NHSBSA) and those transferred from the Department for Work and Pensions (DWP) on 1 November 2021. All figures provided relate to COVID-19 vaccines. Fewer than five Please be aware that I have decided not to release the full details where the total number of individuals falls below five. This is because the individuals could be identified, when combined with other information that may be in the public domain or reasonably available. This information falls under the exemption in section 40 subsections 2 and 3 (a) of the Freedom of Information Act (FOIA). This is because it would breach the first data protection principle as: a - it is not fair to disclose individual’s personal details to the world and is likely to cause damage or distress. b - these details are not of sufficient interest to the public to warrant an intrusion into the privacy of the individual. Please click the below web link to see the exemption in full. www.legislation.gov.uk/ukpga/2000/36/section/40 Breach of Patient confidentiality Please note that the identification of individuals is also a breach of the common law duty of confidence. An individual who has been identified could make a claim against the NHSBSA for the disclosure of the confidential information. The information requested is therefore being withheld as it falls under the exemption in section 41(1) ‘Information provided in confidence’ of the Freedom of Information Act. Please click the below web link to see the exemption in full. https://www.legislation.gov.uk/ukpga/2000/36/section/41 Question 1 The Vaccine Damage Payment Scheme (VDPS) is not a compensation scheme. It provides a one-off tax-free payment, currently £120,000, to successful applicants where, on very rare occasions, a vaccine has caused severe disablement. The total amount of money awarded to claimants is £20,040,000.00. Question 2 The claimant can tell us what happened after vaccination on the claim form. At the medical assessment stage, the independent medical assessor provides a description of the assessed conditions they have been able to identify from the claimant's medical records. This can sometimes be a mixture of conditions. The condition recorded against each claim may therefore be different to the condition initially stated by the claimant on their original claim form. All data provided relates to the conditions listed by the independent medical assessor in the assessment report. 183 Guillain-Barre syndrome (GBS) claims have been received by the VDPS. Question 3 167 claimants have been notified they are entitled to a Vaccine Damage Payment. Question 4 The claimant can tell us what happened after vaccination on the claim form. At the medical assessment stage, the independent medical assessor provides a description of the assessed conditions they have been able to identify from the claimant's medical records. This can sometimes be a mixture of conditions. The condition recorded against each claim may therefore be different to the condition initially stated by the claimant on their original claim form. All data provided relates to the conditions listed by the independent medical assessor in the assessment report. Therefore, the total number of GBS claims awaiting independent medical assessment is unknown. 51 GBS claims have been awarded a Vaccine Damage Payment. 132 GBS claims have been rejected. Question 5 64 GBS claims were unsuccessful because, although the claims met the criteria for causation, the independent medical assessor recommended that the vaccine has not caused severe disablement. Under the VDPS, severe disablement means at least 60% disabled, based on Schedule 2 of The Social Security (General Benefit) Regulations 1982. Question 6 In order to determine if this information is held, we would need to manually review the independent medical assessments for all 64 GBS claims. Using a conservative estimate of 20 minutes per claim we estimate that to review all 64 claims, it would take approx. 19.2 hours to determine if we hold the information and to then provide a figure. Therefore, I estimate that the cost of complying with your request would exceed the non-central Government limit of £450. The limit has been specified in The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 and represents the estimated cost of one person spending 18 hours in determining whether the NHSBSA holds the information, and locating, retrieving and extracting the information. Under Section 12 of the Freedom of Information Act, the NHSBSA is not obliged to comply with your request, and I will not be processing your request further as it currently stands. Question 7 10 individuals within the Parliamentary Constituency of Angus made an application for a Vaccine Damage Payment. We have decided not to disclose the number of claims within each status. This is because disclosure of the figures within this response, may lead to the re-identification of individuals. Therefore, we have withheld this information under section 40 of the FOIA. Question 8 Based on the independent medical assessor’s description of the assessed conditions they have been able to identify from the claimant's medical records, fewer than five GBS claims made from the Parliamentary Constituency of Angus have been received by the VDPS. Therefore, as detailed above in accordance with section 40 (2) and section 41 of FOIA we are unable to provide figures for successful and unsuccessful claims. The claimant can tell us what happened after vaccination on the claim form. At the medical assessment stage, the independent medical assessor provides a description of the assessed conditions they have been able to identify from the claimant's medical records. This can sometimes be a mixture of conditions. The condition recorded against each claim may therefore be different to the condition initially stated by the claimant on their original claim form. All data provided relates to the conditions listed by the independent medical assessor in the assessment report. Therefore, the total number of GBS claims made from the Parliamentary Constituency of Angus awaiting independent medical assessment is unknown.

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.